Results 1 to 10 of about 4,504 (155)

Posaconazole

Journal of Postgraduate Medicine, 2010
Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal and esophageal ...
Bhattacharya, M., Rajeshwari, K., Dhingra, B.   +2 more
core   +6 more sources

Pharmaceutical co-crystals of posaconazole for improvement of physicochemical properties [PDF]

Brazilian Journal of Pharmaceutical Sciences, 2022
Posaconazole exerts an extended spectrum of antifungal activity against various strains of clinically relevant moulds and yeasts. In recent years, antifungal triazole posaconazole has become increasingly important for the prophylaxis and treatment of ...
Monika Nijhawan, Monika Godugu, Trapti Saxena, Talat Farheen, Kanchan Dwivedi   +4 more
doaj   +2 more sources

A Review of Population Pharmacokinetic Models of Posaconazole

Drug Design, Development and Therapy, 2022
Qin Ding,1,* Shuqi Huang,1,* Zexu Sun,2 Kaifeng Chen,1 Xin Li,3 Qi Pei1 1Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, People’s Republic of China; 2Xiangya School of Pharmaceutical Sciences, Central South
Qi Pei, Qin Ding
exaly   +2 more sources

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia

Scientific Reports, 2023
Posaconazole and voriconazole are commonly used for preventing invasive fungal disease (IFD), but few studies compared posaconazole with voriconazole for primary antifungal prophylaxis (PAP) in pediatric acute leukemia.
Songji Tu, Kunlong Zhang, Ningling Wang, Jinhua Chu, Linhai Yang, Zhiwei Xie   +5 more
doaj   +1 more source

Advancing posaconazole quantification analysis with a new reverse-phase HPLC method in its bulk and marketed dosage form [version 2; peer review: 2 approved]

F1000Research, 2023
Introduction: Posaconazole is a widely used antifungal drug, and its accurate quantification is essential for quality control and assessment of its pharmaceutical products.
Srinivas Hebbar, Anup Naha, Abhishek Chaturvedi, Usha Rani, Annamalai Rama, Induja Govindan   +5 more
doaj   +1 more source

Synergistic Interaction of Caspofungin Combined with Posaconazole against FKS Wild-Type and Mutant Candida auris Planktonic Cells and Biofilms

Antibiotics, 2022
Candida auris is a potential multidrug-resistant pathogen able to cause biofilm-associated outbreaks, where frequently indwelling devices are the source of infections.
Noémi Balla, Fruzsina Kovács, Bence Balázs, Andrew M. Borman, Aliz Bozó, Ágnes Jakab, Zoltán Tóth, Ola Kobaissi, László Majoros, Renátó Kovács   +9 more
doaj   +1 more source

Posaconazole and fluconazole prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia

Journal of Microbiology, Immunology and Infection, 2021
Purpose: To assess and compare the efficacy and safety of posaconazole with fluconazole for the prevention of invasive fungal infections in children who were undergoing induction therapy for acute lymphoblastic leukemia (ALL).
Tian Zhang, Jie Bai, Mingxia Huang, Ruixiao Li, Yang Liu, Ansheng Liu, Jixin Liu   +6 more
doaj   +1 more source

Factors associated with subtherapeutic levels of oral posaconazole tablet: a detailed analysis from a tertiary care center in India

International Journal of Infectious Diseases, 2022
Objectives: Posaconazole is a broad-spectrum triazole antifungal, with activity against various clinically important fungi. The delayed release (DR) tablet of posaconazole has been shown to have a superior pharmacokinetic profile in comparison with the ...
Parikshit S. Prayag, Shweta P. Panchakshari, Namita P. Mahalle, Surabhi Dhupad, Sampada A. Patwardhan, Sadanand S. Naik, Sharwari Narawade, Sameer Melinkeri, Amrita P. Prayag   +8 more
doaj   +1 more source

Intravenous-oral itraconazole versus oral posaconazole in preventing invasive fungal diseases for acute leukemia patients

Blood Science, 2023
Invasive fungal diseases (IFDs) are major and lethal infectious complications for patients with neutropenia after chemotherapy. Prophylaxis with intravenous and oral suspended itraconazole (200 mg Q12h intravenously × 2 days followed by 5 mg/kg·d orally ...
Li Liu, Xiaolei Pei, Runzhi Ma, Yi He, Rongli Zhang, Jialin Wei, Qiaoling Ma, Weihua Zhai, Aiming Pang, Erlie Jiang, Mingzhe Han, Donglin Yang, Sizhou Feng   +12 more
doaj   +1 more source

Posaconazole‐induced hypertension in children with cystic fibrosis

Respirology Case Reports, 2021
Posaconazole is a triazole antifungal with a broad spectrum of activity against moulds including Aspergillus spp. Emerging data suggest posaconazole may be effective in the treatment of allergic bronchopulmonary aspergillosis (ABPA) complicating cystic ...
Rachael Marpole, Daniel K. Yeoh, Adelaide L. Withers   +2 more
doaj   +1 more source